Fluidigm

Fluidigm Q3 Revenues Drop 29 Percent on Supply Chain Issues, Waning COVID-19 Testing

Fluidigm Q2 Revenues Grow 19 Percent

Fluidigm Q1 Revenues Grow 19 Percent

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Fluidigm Q4 Revenues Grow 38 Percent on COVID-19-Driven Microfluidics Growth

In Brief This Week: BioReference Laboratories, PerkinElmer, Fluidigm, Invitae, and More

Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Promising Coronavirus Vaccine News Leads to Share-Price Slide for Bevy of Dx Companies

Fluidigm Q3 Revenues Jump 50 Percent Driven by COVID-19 Testing

Fluidigm Shares Rise on Selection of Saliva-Based COVID-19 Assay for Federal Surge Testing

Fluidigm to Offer Coronavirus Saliva Test to US Colleges, Universities at Low Cost

Fluidigm Finalizes $34M NIH Contract for SARS-CoV-2 Assay Production

In Brief This Week: Thermo Fisher Scientific, Fluidigm, Veracyte, and More

Fluidigm Raises $20.9M in Equity Offering, Will Receive $11M After Achieving NIH Milestone

As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

Fluidigm Saliva Test for SARS-CoV-2 Gets FDA Emergency Use Authorization

NIH Awards $249M to Seven Firms for Rapid Acceleration of COVID-19 Diagnostics